Saltar al contenido
Fuerza y músculoRevisión de evidencia3 min read

Sarcopenia in type 2 diabetes: pooled prevalence 18%, higher with older age

Colectivo editorial MoveVitals · Study published · Reading updated

Original paper:The prevalence and risk factors of sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. · Diabetology & metabolic syndrome · 2021 · Artículo original ↗

Idea principal

Across 28 studies of 16,800 people with type 2 diabetes, the pooled prevalence of sarcopenia (loss of muscle mass and function) was 18% (95% CI 0.15-0.22), with older age the clearest risk factor (OR 4.73). Heterogeneity was extreme (I2 = 97.4%) and the abstract repeats one set of estimates for several factors, so most risk-factor numbers are unreliable.

Study design

Revisión de evidencia

Reading basis

Published abstract

Reading focus

Design & applicability

Esta explicación editorial está disponible en inglés, chino simplificado y chino tradicional. Esta interfaz muestra la lectura en inglés.

Pregunta de investigación

Sarcopenia is common in type 2 diabetes, but studies disagree on how common and on who is most at risk. The authors pooled observational studies to estimate prevalence and identify associated factors.

Población y método

Systematic review and meta-analysis of observational studies found by searching PubMed, Embase and the Cochrane Central Register of Controlled Trials. Study quality was rated with the Newcastle-Ottawa scale. Prevalence and associated factors were pooled with random-effects models, and publication bias was checked with a funnel plot and Egger test. The abstract does not state the search end date or the diagnostic criteria for sarcopenia.

Resultados

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    Twenty-eight studies with 16,800 patients were included, and the pooled prevalence of sarcopenia was 18% (95% CI 0.15-0.22; I2 = 97.4%).
  2. 2
    Older age was associated with higher odds of sarcopenia (OR 4.73; 95% CI 4.30-5.19; I2 = 85.6%). Male sex, chronic hyperglycaemia (higher HbA1c) and osteoporosis were also reported as predictors.
  3. 3
    Lower BMI and metformin use were associated with lower risk of sarcopenia.
  4. 4
    The funnel plot and tests showed no obvious publication bias.

Límites e incertidumbre

  1. 1
    An I2 of 97.4% means studies differed greatly, so the single 18% figure hides wide variation between populations and definitions.
  2. 2
    The abstract gives the identical estimate (OR 1.16; 95% CI 1.05-2.47; I2 = 99.2%) for HbA1c, osteoporosis, BMI and metformin, which looks like a reporting error, so those individual effect sizes cannot be trusted.
  3. 3
    Observational studies cannot show that these factors cause sarcopenia, and metformin or BMI findings may reflect who receives treatment.
  4. 4
    This reading is based on the abstract only.

Relevancia práctica

Muscle loss appears to be fairly common among people with type 2 diabetes, especially older people. Do not read the factor list as advice to change medication or body weight; diabetes treatment decisions belong with your clinician. Keeping up strength work and discussing muscle health at check-ups is a reasonable general step.

Tus datos

Grip strength, a chair-stand test, body weight and, if your scale provides it, lean mass trends can be logged over months. Consumer body-composition scales are rough, so compare them only with the same device and conditions.

Cómo interpretar la evidencia

Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.

Resumen estructurado de los autores English

El resumen original en inglés se reproduce con atribución bajo la licencia indicada. Es una fuente, no una interpretación de MoveVitals. El análisis preparado figura arriba; verifica los resultados importantes en la fuente.

Background

Sarcopenia was a frequent chronic complication in patients with type 2 diabetes mellitus (T2DM), and previous evidence showed conflicting results regarding the prevalence and risk factors of sarcopenia in T2DM. In the current study, we aimed at systematically exploring the prevalence and risk factors of sarcopenia in patients with T2DM.

Methods

PubMed, Embase, and Cochrane Central Register of Controlled Trials were systematically searched to identify observational studies which investigated the prevalence and risk factors of sarcopenia in patients with T2DM. The quality of individual included studies was evaluated using The Newcastle-Ottawa scale. Pooled effects regarding prevalence and associated factors were calculated using random-effects models. The potential publication bias was assessed via funnel plot and Egger test.

Results

Twenty-eight studies involving 16,800 patients were included in our meta-analysis. The pooled prevalence of sarcopenia in patients with T2DM was 18% (95% CI 0.15-0.22; I^(2) = 97.4%). The pooled results showed that elder age (OR 4.73; 95% CI 4.30-5.19; I^(2) = 85.6%), male gender, chronic hyperglycemia (higher HbA1c) (OR 1.16; 95% CI 1.05-2.47; I^(2) = 99.2%) and osteoporosis (OR 1.16; 95% CI 1.05-2.47; I^(2) = 99.2%) was predictors for sarcopenia, whereas patients with lower BMI (OR 1.16; 95% CI 1.05-2.47; I^(2) = 99.2%) and metformin administrations (OR 1.16; 95% CI 1.05-2.47; I^(2) = 99.2%) were not prone to get sarcopenia. The funnel plot and statistical tests showed no obvious publication bias.

Conclusions

Sarcopenia was frequent in T2DM patients. Elder age, male gender and chronic hyperglycemia, Osteoporosis were significant risk factors for Sarcopenia. Lower BMI and metformin administrations were associated with lower risk of sarcopenia.

Fuentes y atribución

The prevalence and risk factors of sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Ai Y, Xu R, Liu L.

Diabetology & metabolic syndrome · 2021-09-03

DOI: 10.1186/s13098-021-00707-7 ↗PubMed · 34479652 ↗Europe PMC · Licencia registrada: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

Interpretación editorial de MoveVitals · contenido educativo · sin revisión clínica individual registrada

Fuentes verificadas 2026-11-01

Guías prácticas

Leer en contexto

·Revisión de revisiones

ACSM review of 137 reviews: resistance training works, and few programme details matter

The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.

Medicine & Science in Sports & Exercise

Explicaciones detalladasLeer estudio →
·Metaanálisis de ensayos

Nearly every resistance training plan beat no exercise; heavy loads led for strength

In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.

British Journal of Sports Medicine

Explicaciones detalladasLeer estudio →
·Metaanálisis observacional

Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes

Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.

British Journal of Sports Medicine

Explicaciones detalladasLeer estudio →
·Metaanálisis de ensayos

Protein supplements and weight training: small extra gains, smaller in older adults

Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.

British Journal of Sports Medicine

Explicaciones detalladasLeer estudio →
Fuerza y músculo →